Uwe Rix, Ph.D.
Affiliations: | 2003 | Medical University of South Carolina, Charleston, SC, United States |
Area:
Analytical Chemistry, Biochemistry, Molecular BiologyGoogle:
"Uwe Rix"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Juergen Rohr | grad student | 2003 | MUSC | |
| (Combinatorial biosynthesis of polyketides: Oxygenases in angucycline antibiotic biosynthesis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hu Q, Liao Y, Cao J, et al. (2023) Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib. Chembiochem : a European Journal of Chemical Biology. e202200766 |
| Palve V, Knezevic CE, Bejan DS, et al. (2021) The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chemical Biology |
| Wright GM, Gimbrone NT, Sarcar B, et al. (2021) CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. Plos One. 16: e0252927 |
| Schubert L, Le AT, Estrada-Bernal A, et al. (2021) . Molecular Pharmacology |
| Palve V, Liao Y, Remsing Rix LL, et al. (2020) Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in Cancer Biology |
| Cocco E, Lee JE, Kannan S, et al. (2020) Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors Cancer Research. 80: 5680-5680 |
| Remsing Rix L, Sumi N, Bryant A, et al. (2020) B40 IGF-Binding Protein-Mediated Sensitization of EGFR-Mutant NSCLC Cells to Osimertinib by Cancer-Associated Fibroblast Journal of Thoracic Oncology. 15: S38 |
| Xie M, Zheng H, Madan-Lala R, et al. (2019) MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer. Cancer Research |
| Sarcar B, Gimbrone NT, Wright G, et al. (2019) Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. Febs Open Bio |
| Sumi NJ, Ctortecka C, Hu Q, et al. (2019) Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chemical Biology |